Abstract: This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.
Abstract: Disclosed are topical compositions and methods of treatment of a skin or mucosal disorder selected from palmoplantar psoriasis, hereditary palmoplantar keratoderma, acquired palmoplantar keratoderma, hydradenitis suppurativa, dermatitis, ichthyosis vulgaris, hereditary ichthyosis, acquired ichthyosis, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, Gorlin syndrome, nail psoriasis, flexural/inverse psoriasis, non-melanoma skin cancer, Cutaneous T-cell lymphoma and precancerous skin, mucosal and nail lesions, by once or twice daily topical administration to a subject of a composition comprising therapeutically effective amount of tapinarof.
Abstract: Disclosed are simple yet stable and effective compositions comprising from about 1% to about 5% by weight of the composition of a minocycline or mixtures thereof and pharmaceutically acceptable ingredients comprising from about 60% to about 99% by weight of the composition of at least one hydrophobic oil, and from about 5% to about 25% by weight of the composition of at least one fatty alcohol, wherein the at least one hydrophobic oil and the at least one fatty alcohol are sufficient to ensure the pharmaceutically acceptable assay stability of the minocycline in the composition under 3 months accelerated stability conditions at 40° C./75% RH. Also disclosed are methods of treatment of acne, rosacea and impetigo.
Abstract: The present invention relates to the treatment of an ocular inflammatory disease or an ocular degeneration disease by ophthalmic administration of a composition comprising tapinarof and optionally at least one additional active agent. Specifically, the ocular inflammatory disease is blepharitis. This invention provides a treatment of blepharitis and Demodex mites.
Abstract: The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.
Type:
Application
Filed:
November 9, 2021
Publication date:
March 3, 2022
Applicant:
Sol-Gel Technologies Ltd.
Inventors:
Moshe ARKIN, Marcel ZIGHELBOIM, Ofra LEVY-HACHAM, Ori NOV
Abstract: Provided herein is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w tazarotene and a carrier suitable for topical administration. Also provided is a topical combination composition comprising from about 0.25% w/w to about 2.0% w/w tapinarof, from about 0.025% w/w to about 0.1% w/w w tazarotene, from about 0.01% w/w to about 0.25% w/w at least one corticosteroid of potency class 1-4 and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of plaque psoriasis and exhibit synergistic and/or additive effects which allow reducing the amounts of the active agents in the compositions. The addition of tazarotene to tapinarof potentiates the tapinarof anti-psoriatic therapeutic effect.
Abstract: Disclosed are topical compositions and methods of treatment of skin disorders selected from Molluscum contagiosum, verrucae and warts by topical administration to a subject in need thereof of a composition comprising between about 0.5%-1.0% w/w high-purity cantharidin. Also disclosed are processes for preparation of high-purity cantharidin.
Abstract: Provided herein are topical combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.
Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
Abstract: This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.
Abstract: The present invention, in some embodiments thereof, relates to a topical composition for use in treating, preventing, alleviating and/or ameliorating pruritus, wherein the composition comprises tapinarof and the pruritus is not associated with atopic dermatitis, psoriasis or any combination thereof.
Abstract: The present invention is directed to a composition comprising aryl hydrocarbon receptor (AhR) agonists and combinations for the prevention and treatment of alopecia and hair loss, e.g. when such conditions are caused by chemotherapy, radiation therapy or hormone replacement therapy.
Type:
Application
Filed:
April 12, 2021
Publication date:
October 14, 2021
Applicant:
Sol-Gel Technologies Ltd.
Inventors:
Ori Nov, Marcel Zighelboim, Karine Neimann
Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.
Abstract: The present invention relates to the treatment, prevention or alleviation of a gastrointestinal disorder caused by one or more intestinal helminths, said treatment, prevention or alleviation comprises administering a topical composition comprising a peroxide to a subject in need thereof.
Abstract: Provided herein is a topical combination composition comprising roflumilast, roflumilast N-oxide or pharmaceutically acceptable salt thereof, and at least one additional active agent selected from a retinoid, benzoyl peroxide (BPO) and combinations thereof. The active agents in the composition of this invention are in encapsulated or non-encapsulated form, according to need. The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from acne and rosacea and exhibits synergistic and/or additive effects allowing to reduce the active agents amounts in the topical combination compositions.
Abstract: Provided herein is a topical composition comprising roflumilast, roflumilast N-oxide or salts thereof as an active agent. The active agent in the composition of this invention is in encapsulated or non-encapsulated form, according to need. The above composition is useful for the treatment, prevention or alleviation of a skin disorder selected from Hidradenitis suppurativa and Prurigo nodularis.
Abstract: The present invention provides core-stabilized microcapsules, wherein said core comprises at least one active agent encapsulated within an inorganic oxide shell, processes for their preparations, comparisons comprising them and uses thereof.
Abstract: The present invention, in some embodiments thereof, relates to topical compositions and methods of treatment, prevention and/or amelioration of granuloma annulare, a non-infection granulomatous disease, or a subcutaneous inflammation by topical or intralesional administration of compositions comprising tapinarof.